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ABSTRACT
Poor adherence to medication is a major public health challenge. Here, we aimed to determine the adherence to
oral and topical medications and to analyze underlying associated factors using the translated Japanese version
of Morisky Medication Adherence Scale-8 regarding urticaria treatment. Web-based questionnaires were per-
formed for 3096 registered dermatological patients, along with a subanalysis of 751 registered urticaria patients
in this study. The adherence to oral medication was significantly associated with the frequency of hospital visits.
Variables that affected the adherence to topical medication included age and experience of drug effectiveness.
The rate of responses that “It felt like the symptoms had improved” varied significantly among the dermatological
diseases treated with oral medications. Dermatologists should be aware that adherence to the treatment of urti-
caria is quite low. Regular visits and active education for patients with urticaria are mandatory in order to achieve
a good therapeutic outcome by increasing the adherence.
Key words: adherence, oral, topical, transient improvement, urticaria.
INTRODUCTION
Urticaria is one of the most common skin diseases and is char-
acterized by the appearance of itchy wheals and flares that
usually disappear within hours.1 “Spontaneous urticaria” is the
most common type, in which wheals develop spontaneously
over the course of a day. It consists of acute (spontaneous)
urticaria and chronic (spontaneous) urticaria, in which wheals
occur for less than 6 weeks or 6 weeks or more, respectively.2
In Japan, the term “chronic urticaria” is used to represent, on
some occasions, urticaria that continues for more than
1 month regardless of the presence of triggers.1
The medication adherence of patients with acute urticaria
does not seem to affect the outcome, because it is usually
self-limiting. However, in chronic urticaria, poor adherence
often results in the failure of treatment and the relapse of
symptoms. Recently, an eight-item self-reporting scale was
developed by Morisky et al.,3 called the Morisky Medication
Adherence Scale-8 (MMAS-8). Although this scale originally
targeted oral medication for hypertensive patients, we recently
assessed the medication adherence for oral and topical reme-
dies using a translated Japanese version of MMAS-8.4,5 We
also performed a subanalysis of 751 registered patients with
urticaria in this study.
Correspondence: Sakae Kaneko, M.D., Department of Dermatology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo City,
Shimane 693-8501, Japan. Email: kanekos2@med.shimane-u.ac.jp
Received 16 March 2015; accepted 26 April 2015.
1078 © 2015 The Authors. The Journal of Dermatology published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Dermatological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs
License, which permits use and distribution in any medium, provided the original work is properly cited, the use is
non-commercial and no modifications or adaptations are made.
doi: 10.1111/1346-8138.12971 Journal of Dermatology 2015; 42: 1078–1082
METHODS
This study was conducted among patients registered in a mon-
itoring system established by Macromill (Tokyo, Japan) which
has been described elsewhere.4,5 Our Web-based question-
naire included questions on the following items: age, sex, mari-
tal status, annual income, employment status, educational
status, smoking habit, alcohol consumption, frequency of hos-
pital visits, disease duration, main health-care institution, oral
or topical medication, experience of the effectiveness of oral
medication, experience of the effectiveness of topical medica-
tion, experience of adverse events associated with oral medi-
cation, experience of adverse events associated with topical
medication and overall satisfaction with treatment, as well as
MMAS-8 for oral medication and MMAS-8 for topical medica-
tion.
The characteristics of the whole sample and of the groups
with different levels of adherence in terms of the MMAS-8
score are presented. The v2-test for categorical variables or
ANOVA for continuous variables was used to evaluate the differ-
ences in the study variables among the three adherence
groups. Internal consistency was assessed using Cronbach’s
alpha. An acceptable Cronbach’s alpha value is considered to
be 0.7 or more.6 Known group validity was assessed through
the association of items and MMAS categories using correla-
tion coefficient and covariance. All analyses were performed
using STATA version 9 (StataCorp, College Station, TX, USA).
The significance level was set at P < 0.05.
RESULTS
Demographic data of the 751 patients with urticaria are sum-
marized in Table 1. The mean age of these subjects was
45.4 years (range, 17–80) and 33.6% of them were male.
Among these 751 patients, a total of 673 took oral medication
and 528 were treated with topical medication. Mean adherence
scores by MMAS-8 were 4.9 for oral and 4.2 for topical medi-
cation. The reliability scores (i.e. Cronbach’s alpha) were 0.683
for oral MMAS-8 and 0.726 for topical MMAS-8, which demon-
strated moderate to high reliability of the Japanese version of
MMAS-8.
As shown in Table 2, the adherence to oral medication was
significantly associated with the frequency of hospital visits.
Variables that affected the adherence to topical medication
were age, disease duration and experience of drug effective-
ness.
Among the 673 urticaria patients with oral drugs, 75 (11.1%)
admitted that they ignored doctors’ instructions, whereas 124
of the 528 (23.5%) urticaria patients with topical remedies did
so. Although 29.0% (36/124) of patients stopped applying topi-
cal remedies because they thought their lesion had been
cured, significantly more patients (48.0%; 36/75) stopped oral
drugs due to the same reason, suggesting that the adherence
to oral drugs could be affected more by patients’ own deci-
sions regarding continued medication use (Table 3). Factors
that influence adherence to oral and topical medication
were investigated. Patients’ reasons for not adhering to their
Table 1. Basic characteristics of urticaria patients (n = 751)
Characteristics n %
Age, mean (SD, range), years 45.4 (11.7, 17–80)
Sex
Male 252 33.6
Female 499 66.4
Marital status
Married 270 36.0
Unmarried 481 64.0
Annual income
≥¥6 million 266 40.6
<¥6 million 389 59.4
Employment
Employed 453 62.8
Unemployed 268 37.2
Education
University graduate 306 41.1
Not university graduate 439 58.9
Smoking
Smoker 147 19.7
Non-smoker 600 80.3
Alcohol
≥Once a month 430 57.6
<Once a month 317 42.4
Frequency of MD visits
≥Once a half-year 637 84.8
<Once a half-year or unknown 114 15.2
Disease duration
<Half a year 179 23.8
≥Half a year to 1 year 169 22.5
>1–3 years 168 22.4
>3–5 years 71 9.5
>5–10 years 79 10.5
>10–20 years 45 6.0
>20 years 40 5.3
Main health-care institution
University hospital 25 3.4
Municipal hospital 135 18.1
Private clinic or other 586 78.6
Oral medication
Experience of drug effectiveness
Yes 611 90.8
No 62 9.2
Experience of adverse events
Yes 124 18.4
No 549 81.6
Topical medication
Experience of drug effectiveness
Yes 443 83.9
No 85 16.1
Experience of adverse events
Yes 51 9.7
No 477 90.3
Overall satisfaction with treatment
>Satisfied 440 58.6
<Satisfied 311 41.4
Adherence, mean (SD, range)
Oral medication 4.9 (1.9, 0.25–8)
Topical medication 4.2 (2.1, 0–8)
Cronbach’s alpha of adherence measure
Oral medication 0.683
Topical medication 0.726
SD, standard deviation.
1079© 2015 The Authors. The Journal of Dermatology published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Dermatological Association.
Adherence of urticaria
T
a
b
le
2
.
P
re
va
le
n
c
e
o
f
s
tu
d
y
v
a
ri
a
b
le
s
fo
r
th
e
th
re
e
a
d
h
e
re
n
c
e
le
v
e
ls
a
m
o
n
g
u
rt
ic
a
ri
a
p
a
ti
e
n
ts
:
o
ra
l
a
n
d
to
p
ic
a
l
m
e
d
ic
a
ti
o
n
C
h
a
ra
c
te
ri
s
ti
c
s
O
ra
l
m
e
d
ic
a
ti
o
n
(n
=
6
7
3
)
T
o
p
ic
a
l
m
e
d
ic
a
ti
o
n
(n
=
5
2
8
)
H
ig
h
a
d
h
e
re
n
c
e
M
e
d
iu
m
a
d
h
e
re
n
c
e
L
o
w
a
d
h
e
re
n
c
e
P
H
ig
h
a
d
h
e
re
n
c
e
M
e
d
iu
m
a
d
h
e
re
n
c
e
L
o
w
a
d
h
e
re
n
c
e
P
n
=
6
2
(9
.2
%
)
n
=
1
7
1
(2
5
.4
%
)
n
=
4
4
0
(6
5
.4
%
)
n
=
3
3
(6
.3
%
)
n
=
9
7
(1
8
.4
%
)
n
=
3
9
8
(7
5
.4
%
)
A
g
e
,
m
e
a
n
(S
D
),
y
e
a
rs
4
7
.7
(1
0
.8
)
4
6
.0
(1
1
.2
)
4
5
.0
(1
2
.1
)
0
.1
9
4
4
8
.6
(1
1
.2
)
4
7
.8
(1
2
.4
)
4
4
.9
(1
2
.3
)
0
.0
4
1
S
e
x M
a
le
2
3
(1
0
.3
)
5
7
(2
5
.5
)
1
4
4
(6
4
.3
)
0
.7
9
2
8
(4
.6
)
3
5
(2
0
.1
)
1
3
1
(7
5
.3
)
0
.4
5
8
F
e
m
a
le
3
9
(8
.7
)
1
1
4
(2
5
.4
)
2
9
6
(6
5
.9
)
2
5
(7
.1
)
6
2
(1
7
.5
)
2
6
7
(7
5
.4
)
M
a
ri
ta
l
s
ta
tu
s
M
a
rr
ie
d
1
8
(7
.4
)
6
0
(2
4
.6
)
1
6
6
(6
8
.0
)
0
.3
8
4
1
0
(5
.1
)
3
7
(1
8
.9
)
1
4
9
(7
6
.0
)
0
.6
9
8
U
n
m
a
rr
ie
d
4
4
(1
0
.3
)
1
1
1
(2
5
.9
)
2
7
4
(6
3
.9
)
2
3
(6
.9
)
6
0
(1
8
.1
)
2
4
9
(7
5
.0
)
A
n
n
u
a
l
in
c
o
m
e
≥¥
6
m
ill
io
n
2
6
(1
1
.0
)
6
0
(2
5
.4
)
1
5
0
(6
3
.6
)
0
.5
9
1
1
2
(6
.7
)
3
3
(1
8
.5
)
1
3
3
(7
4
.7
)
0
.8
3
6
<
¥6
m
ill
io
n
3
0
(8
.5
)
9
1
(2
5
.8
)
2
3
2
(6
5
.7
)
1
6
(5
.7
)
4
9
(1
7
.4
)
2
1
7
(7
7
.0
)
E
m
p
lo
y
m
e
n
t
E
m
p
lo
y
e
d
3
3
(8
.0
)
1
0
7
(2
6
.1
)
2
7
0
(6
5
.9
)
0
.3
4
8
1
5
(4
.8
)
6
0
(1
9
.3
)
2
3
6
(7
5
.9
)
0
.1
0
0
U
n
e
m
p
lo
y
e
d
2
7
(1
1
.5
)
6
0
(2
5
.5
)
1
4
8
(6
3
.0
)
1
8
(9
.2
)
3
0
(1
5
.4
)
1
4
7
(7
5
.4
)
E
d
u
c
a
ti
o
n
U
n
iv
e
rs
it
y
g
ra
d
u
a
te
2
2
(7
.9
)
7
4
(2
6
.6
)
1
8
2
(6
5
.5
)
0
.6
1
6
1
2
(5
.6
)
4
4
(2
0
.4
)
1
6
0
(7
4
.1
)
0
.5
3
6
N
o
t
u
n
iv
e
rs
it
y
g
ra
d
u
a
te
3
9
(1
0
.0
)
9
7
(2
4
.9
)
2
5
4
(6
5
.1
)
2
1
(6
.8
)
5
2
(1
6
.9
)
2
3
5
(7
6
.3
)
S
m
o
k
in
g
S
m
o
k
e
r
1
0
(7
.8
)
3
3
(2
5
.8
)
8
5
(6
6
.4
)
0
.8
2
2
6
(5
.4
)
2
2
(1
9
.6
)
8
4
(7
5
.0
)
0
.8
6
1
N
o
n
-s
m
o
k
e
r
5
2
(9
.6
)
1
3
8
(2
5
.5
)
3
5
2
(6
4
.9
)
2
7
(6
.6
)
7
5
(1
8
.2
)
3
1
0
(7
5
.2
)
A
lc
o
h
o
l
≥O
n
c
e
a
m
o
n
th
3
3
(8
.6
)
8
7
(2
2
.8
)
2
6
2
(6
8
.6
)
0
.1
0
4
1
8
(5
.9
)
4
9
(1
6
.1
)
2
3
8
(7
8
.0
)
0
.1
9
0
<
O
n
c
e
a
m
o
n
th
2
9
(1
0
.1
)
8
4
(2
9
.2
)
1
7
5
(6
0
.8
)
1
5
(6
.8
)
4
8
(2
1
.9
)
1
5
6
(7
1
.2
)
F
re
q
u
e
n
c
y
o
f
h
o
s
p
it
a
l
v
is
it
s
≥O
n
c
e
a
h
a
lf
-y
e
a
r
6
0
(1
0
.3
)
1
3
6
(2
3
.4
)
3
8
6
(6
6
.3
)
0
.0
0
1
2
9
(6
.6
)
7
6
(1
7
.2
)
3
3
6
(7
6
.2
)
0
.2
7
6
<
O
n
c
e
a
h
a
lf
-y
e
a
r
o
r
u
n
k
n
o
w
n
2
(2
.2
)
3
5
(3
8
.5
)
5
4
(5
9
.3
)
4
(4
.6
)
2
1
(2
4
.1
)
6
2
(7
1
.3
)
D
is
e
a
se
d
u
ra
ti
o
n
<
H
a
lf
a
y
e
a
r
1
6
(1
0
.3
)
4
7
(3
0
.1
)
9
3
(5
9
.6
)
0
.3
1
1
1
7
(1
1
.5
)
2
8
(1
8
.9
)
1
0
3
(6
9
.6
)
0
.0
1
7
≥H
a
lf
a
y
e
a
r
to
1
y
e
a
r
8
(5
.8
)
4
0
(2
9
.0
)
9
0
(6
5
.2
)
4
(3
.1
)
2
8
(2
1
.4
)
9
9
(7
5
.6
)
>
1
–3
y
e
a
rs
1
5
(9
.4
)
3
6
(2
2
.6
)
1
0
8
(6
7
.9
)
6
(5
.4
)
2
4
(2
1
.6
)
8
1
(7
3
.0
)
>
3
y
e
a
rs
2
3
(1
0
.5
)
4
8
(2
1
.8
)
1
4
9
(6
7
.7
)
6
(4
.4
)
1
7
(1
2
.3
)
1
1
5
(8
3
.3
)
M
a
in
h
e
a
lt
h
-c
a
re
in
s
ti
tu
ti
o
n
U
n
iv
e
rs
it
y
h
o
s
p
it
a
l
3
(1
3
.0
)
5
(2
1
.7
)
1
5
(6
5
.2
)
0
.8
5
9
†
0
(0
.0
)
5
(2
9
.4
)
1
2
(7
0
.6
)
0
.4
7
4
†
M
u
n
ic
ip
a
l
h
o
s
p
it
a
l
1
0
(8
.6
)
2
7
(2
3
.1
)
8
0
(6
8
.4
)
6
(6
.5
)
2
0
(2
1
.5
)
6
7
(7
2
.0
)
P
ri
v
a
te
c
lin
ic
o
r
o
th
e
r
4
8
(9
.1
)
1
3
9
(2
6
.2
)
3
4
3
(6
4
.7
)
2
7
(6
.5
)
6
9
(1
6
.6
)
3
1
9
(7
6
.9
)
E
x
p
e
ri
e
n
c
e
o
f
d
ru
g
e
ff
e
c
ti
v
e
n
e
s
s
Y
e
s
5
8
(9
.5
)
1
5
7
(2
5
.7
)
3
9
6
(6
4
.8
)
0
.5
7
5
3
0
(6
.8
)
8
8
(1
9
.9
)
3
2
5
(7
3
.4
)
0
.0
4
9
N
o
4
(6
.5
)
1
4
(2
2
.6
)
4
4
(7
1
.0
)
3
(3
.5
)
9
(1
0
.6
)
7
3
(8
5
.9
)
E
x
p
e
ri
e
n
c
e
o
f
a
d
v
e
rs
e
e
v
e
n
ts
Y
e
s
1
0
(8
.1
)
3
2
(2
5
.8
)
8
2
(6
6
.1
)
0
.8
8
7
2
(3
.9
)
1
0
(1
9
.6
)
3
9
(7
6
.5
)
0
.8
6
4
†
N
o
5
2
(9
.5
)
1
3
9
(2
5
.3
)
3
5
8
(6
5
.2
)
3
1
(6
.5
)
8
7
(1
8
.2
)
3
5
9
(7
5
.3
)
O
v
e
ra
ll
s
a
ti
s
fa
c
ti
o
n
w
it
h
tr
e
a
tm
e
n
t
>
S
a
ti
s
fi
e
d
3
7
(9
.4
)
1
0
9
(2
7
.8
)
2
4
6
(6
2
.8
)
0
.2
0
5
2
2
(7
.0
)
6
0
(1
9
.1
)
2
3
2
(7
3
.9
)
0
.5
5
8
<
S
a
ti
s
fi
e
d
2
5
(8
.9
)
6
2
(2
2
.1
)
1
9
4
(6
9
.0
)
1
1
(5
.1
)
3
7
(1
7
.3
)
1
6
6
(7
7
.6
)
†
F
is
h
e
r’
s
e
x
a
c
t
te
s
t.
S
D
,
s
ta
n
d
a
rd
d
e
v
ia
ti
o
n
.
1080 © 2015 The Authors. The Journal of Dermatology published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Dermatological Association.
S. Kaneko et al.
doctors’ instructions were explored. As shown in Table 3, the
rate of responses that “It felt like the symptoms had improved”
varied significantly among the four skin diseases treated with
oral medications. There was no significant difference in the
rates of patient adherence to topical treatment plans among
the four diseases.
DISCUSSION
Demographic data showed that at least 76.2% of patients suf-
fered from chronic urticaria (for half a year or longer, Table 1),
although the subtypes of urticaria (e.g. spontaneous or induc-
ible) were unknown. Previous reports showed that approxi-
mately 70% of patients with urticaria suffered from the
spontaneous type.7,8 Therefore, at least half of the patients
with urticaria in this survey could be classified as having
chronic spontaneous urticaria. The proportion of female
patients (66.4%) was approximately double that of the male
ones (33.6%). In addition, the percentage of patients aged in
their 30s to 50s, in the prime of life, was 82.3%. These demo-
graphic data are compatible with previous investigations on
chronic urticaria.9,10
In our Web-based questionnaires, the patients were asked
whether or not they had received medical treatment at a medi-
cal institution in the past year. The patients who answered that
they had received medical treatment for atopic dermatitis, urti-
caria, psoriasis or tinea were asked the following additional
question: “How much time has passed since you were diag-
nosed with that skin disease?”. Thus, patients who answered
this question might have included patients with acute urticaria.
Because the symptom of acute urticaria resolves in a short
time, these patients have fewer adherence-related problems,
and may have better adherence to medication. Actually, in
topical medication, patients with a disease duration of less
than 6 months demonstrated significantly better adherence.
However, in oral medication, no significant difference was
observed in adherence between patients with different disease
durations. This implies that patients with urticaria who require
oral medication have poor adherence to medication irrespec-
tive of disease duration. In future study, we believe that we
need to perform specific selection of patients with chronic
spontaneous urticaria, in whom poor adherence is often
observed (Table 2).
Adherence refers to patients actively participating in the
therapeutic decision-making process and being treated
accordingly.11 Improving adherence via patient–doctor commu-
nication is essential for proper treatment. Common causes of
poor adherence include a high frequency of medication admin-
istration, denial of the existence of an illness, a lack of under-
standing of the benefits of medication and cost.12 In Europe,
treatment in accordance with guidelines improved adherence,
so the early application of guideline-based chronic urticaria
management may be a cost-effective way to improve out-
comes.13
For urticaria, the dose of oral medication (antihistamines)
required for remission is dependent on the individual. Intermi-
nable treatment may lead to poor adherence. Among the four
groups of dermatology patients (atopic dermatitis, urticaria,
psoriasis and tinea), those with urticaria showed the poorest
adherence, followed by those with atopic dermatitis.4 Com-
pared with patients with hypertension and diabetes, with whom
comparative studies were conducted, patients with urticaria
showed poorer adherence.3,14 The reasons for such poor
adherence are believed to be as follows: symptoms with fluctu-
ating severity, the ease with which patients can stop treatment
by themselves and low disease severity (not life-threatening).
Although advances in Japanese health care have made treat-
ment accessible at any time at low cost, atopic dermatitis and
urticaria are diseases that significantly impair the quality of life
of patients,15 so poor adherence should not be ignored.
In conclusion, to improve adherence to urticaria treatment,
patients should be aware of the importance of continuing oral
medication for a certain period proactively, even if they do not
have any symptoms. Concurrently, evidence is needed to show
how long patients should continue oral medications depending
on the severity and duration of urticaria. Furthermore, the evi-
dence-based treatment guidelines for urticaria should be
widely accepted by not only dermatologists, but also primary
physicians.
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